Hui Zhou

2.7k total citations · 1 hit paper
104 papers, 1.3k citations indexed

About

Hui Zhou is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Hui Zhou has authored 104 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pathology and Forensic Medicine, 35 papers in Molecular Biology and 32 papers in Oncology. Recurrent topics in Hui Zhou's work include Lymphoma Diagnosis and Treatment (35 papers), Viral-associated cancers and disorders (10 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Hui Zhou is often cited by papers focused on Lymphoma Diagnosis and Treatment (35 papers), Viral-associated cancers and disorders (10 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Hui Zhou collaborates with scholars based in China, United States and Germany. Hui Zhou's co-authors include Ling Xiao, Li Xiong, Wei Chen, Yongxiang Wang, Yu Wen, Zhongtao Liu, Yuping Ran, Xin Ran, Yajun Li and Eric Amador and has published in prestigious journals such as Science, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hui Zhou

95 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Colorectal liver metastasis: molecular mechanism and interventional therapy

2022 176 citations Hui Zhou et al. profile →

Peers

Countries citing papers authored by Hui Zhou

Since Specialization

Citations

This map shows the geographic impact of Hui Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui Zhou more than expected).

Fields of papers citing papers by Hui Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui Zhou. The network helps show where Hui Zhou may publish in the future.

Co-authorship network of co-authors of Hui Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Hui Zhou. A scholar is included among the top collaborators of Hui Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui Zhou. Hui Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Luvometinib in patients with Langerhans cell histiocytosis, Erdheim–Chester disease, and other histiocytic neoplasms: a single-arm, multicentre, phase 2 study 2025 ·EClinicalMedicine ·Xinxin Cao, Qi Zhu, Zhen Cai, Jie Ma, Hui Zhou, (unknown), Lai‐ping Zhong, (unknown), Xingli Wang, (unknown), (unknown), (unknown), (unknown), (unknown), Li J	1
2	High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study 2025 ·Blood Cancer Discovery ·Yan Gao, (unknown), (unknown), (unknown), Zhiming Li, Hui Zhou, (unknown), (unknown), (unknown), Cheng Huang, (unknown), (unknown), (unknown), Huiqiang Huang	3
3	Photonic logic tensor computing beyond Tbit/s per core 2025 ·Optica ·Wenkai Zhang, Bo Wu, (unknown), Hui Zhou, Weida Hu, Tingchao He, L. Chen, (unknown), Dongmei Huang, Yang Zhao, Wei Wang, (unknown), (unknown), (unknown), Jianji Dong, Xinliang Zhang	0
4	Photothermal‐Photocatalysis System by Photosensitive Covalent Organic Framework@Wood for Efficient Solar‐Driven Water Evaporation and Uranium Removal 2025 ·Advanced Functional Materials ·(unknown), (unknown), Jiqiao Zhang, Yujie Zhao, Hui Zhou, Tiantian Wu, (unknown), (unknown), Dan Tian	1
5	3D Printing of Proteins Via Temperature‐Dependent Amyloid Aggregation 2024 ·Advanced Functional Materials ·(unknown), Yanyun Pang, Jinrui Zhang, (unknown), Yong‐Chun Liu, Min Li, Jinhua Song, (unknown), Zhengge Wang, (unknown), (unknown), Hui Zhou, Jinglin Wang, Jianing Ma, (unknown), Xu Zhang, Jian Zhao, Peng Yang	7
6	Causal association between Parkinson’s disease and cancer: a bidirectional Mendelian randomization study 2024 ·Frontiers in Aging Neuroscience ·Chunyan Tang, Ping Fu, (unknown), Hui Zhou, (unknown), Yang Li, (unknown)	2
7	Primary breast diffuse large B‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group 2023 ·Cancer Medicine ·(unknown), (unknown), Huangming Hong, (unknown), Le Yu, (unknown), Zhihui Zhang, Liqun Zou, Bo Zhu, Hui Zhou, Xianling Liu, Yao Liu, Hongqiang Guo, He Huang, Tongyu Lin	2
8	A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first‐line therapy in patients with newly diagnosed, stage I–II extranodal natural‐killer/T‐cell lymphoma 2023 ·American Journal of Hematology ·Peng Sun, Yajun Li, Cong Li, (unknown), Yu Wang, Hang Yang, (unknown), Wenqi Jiang, Liqun Zou, Haiyan Yang, Hui Zhou, Zhiming Li	9
9	A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma 2023 ·Blood ·Huangming Hong, Mingzhi Zhang, Zhigang Peng, Jianzhen Shen, Yue-Rong Shuang, Hui Zhou, Hongqiang Guo, He Huang, Fei Li, Zhengzi Qian, Lihong Liu, Liang Wang, Wei Yang, Liling Zhang, Pengcheng He, Qian Shen, Fugen Li, (unknown), Tongyu Lin	2
10	Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26) 2023 ·Blood ·Jie Jin, Qingqing Cai, Liling Zhang, Liqun Zou, Zengjun Li, (unknown), Keshu Zhou, Lihua Qiu, (unknown), Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, (unknown), (unknown), Lijia Chen	3
11	Successful Treatment of Primary CNS Extranodal NK/T-Cell Lymphoma with Surgery and Chemotherapy Combined with Sintilimab: A Case Report and Literature Review 2022 ·SHILAP Revista de lepidopterología ·Liping Qin, Yajun Li, (unknown), (unknown), Tao Pan, (unknown), Ling Xiao, Hui Zhou	3
12	Declines in PDE4B activity promote myopia progression through downregulation of scleral collagen expression 2021 ·Experimental Eye Research ·Fuxin Zhao, Hui Zhou, Wei Chen, Chenchen Zhao, (unknown), Yijin Tao, Miaozhen Pan, Peter S. Reinach, (unknown), Jianhong An, (unknown), Jiang‐Fan Chen, Huifang Tang, Changqing Zeng, Jia Qu, Xiangtian Zhou	19
13	Lycorine targets multiple myeloma stem cell‐like cells by inhibition of Wnt/β‐catenin pathway 2020 ·British Journal of Haematology ·(unknown), (unknown), Long Liang, Ling Xiao, Hui Yi, Mao Ye, Mridul Roy, Jiliang Xia, Wen Zhou, (unknown), (unknown), Boxin Zhang, Zhenzhen Li, Jing Liu, Hui Zhou, Xiaojuan Xiao	16
14	The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma 2020 ·British Journal of Haematology ·Long Liang, Yanjuan He, (unknown), Hui Zhou, Ling Xiao, Mao Ye, (unknown), (unknown), (unknown), Peifu Feng, (unknown), Wenjie Cao, Taohua Liu, Mridul Roy, Xiaojuan Xiao, Jing Liu	17
15	<p>Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis</p> 2020 ·Therapeutics and Clinical Risk Management ·Jin Li, Yajun Li, (unknown), (unknown), Meizuo Zhong, Xianling Liu, (unknown), (unknown), (unknown), Lijun Huang, Ling Xiao, Hui Zhou	1
16	A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma 2019 ·Frontiers in Oncology ·Nan Shen, Jun Du, Hui Zhou, Nan Chen, Yi Pan, Jörg D. Hoheisel, (unknown), Ling Xiao, Yue Tao, Xi Mo	31
17	Cerebral Function of Bone Marrow Multipotent Adult Progenitor Cells After Transplantation in Parkinson's Disease Rat Models 2013 ·Transplantation Proceedings ·(unknown), Hui Zhou, (unknown), (unknown), (unknown), Haiwei Xu, (unknown)	3
18	[Correlation between podoplanin-positive lymphatic microvessel density and CT characteristics of non-small cell lung cancer]. 2012 ·SHILAP Revista de lepidopterología ·Hui Zhou, Zeng Xiong, Jinkang Liu, Shengxi Chen, (unknown), (unknown)	2
19	Lymphatic Microvessel Density Combined with CT Used in the Diagnosis of Mediastinal and Hilar Lymph Node Metastasis of Non-small Cell Lung Cancer 2012 ·Archives of Medical Research ·Hui Zhou, Jinkang Liu, (unknown), Zeng Xiong, Guo‐Qiang Lin, (unknown), Wei Chen, (unknown)	4
20	Role of Immature Microvessels in Assessing the Relationship between CT Perfusion Characteristics and Differentiation Grade in Lung Cancer 2010 ·Archives of Medical Research ·Zeng Xiong, Jinkang Liu, Chengping Hu, Hui Zhou, (unknown), Wei Chen	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact